Liposomal amphotericin B treatment for neonatal fungal infections

Pediatric Infectious Disease Journal

Volumn 17, Issue 2, 1998, Pages 146-148

  Scarcella, Alda ^a   Pasquariello, Maria B ^a   Giugliano, Brunella ^a   Vendemmia, Maria ^a   De Lucia, Amalia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Fungal infection; Liposomal amphotericin B; Newborn infant

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; CANDIDA ALBICANS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; FUNGAL MENINGITIS; HUMAN; MYCOSIS; NEWBORN; NEWBORN INFECTION; PREMATURITY; PRIORITY JOURNAL; SURVIVAL; VERY LOW BIRTH WEIGHT;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LIPOSOMES; MYCOSES;

EID: 0031950695     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199802000-00013     Document Type: Article

References (15)

1. Baley JM, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin-B and 5-flurocytosine in neonates. J Pediatr 1990;116:791-7.
2. Johnson DE, Thompson TR, Green TP, Ferrieri P. Systemic candidiasis in very low-birth-weight infants (<1500 grams). Pediatrics 1984;73:138-43.
3. Weese-Majer DE, Wheeler Fondriest D, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987;6:190-6.
4. Ng PC. Systemic fungal infections in neonates. Arch Dis Child 1994; 71:F130-5.
5. Emminger W, Lang HRM, Emminger-Schmidmeier W, Peters C, Gadner H. Amphotericin B serum levels in pediatric bone marrow transplant recipients. Bone Marrow Transplant 1991;7:95-9.
6. Zoubeck A, Emminger W, Emminger-Schmidmeier W, et al. Conventional vs liposomal amphotericin B in immunosuppressed children. Pediatr Hematol Oncol 1992;9:187-90.
7. Katz NM, Pierce PF, Anzeck RA, et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant 1990;9:14-7.
8. Meunier F, Prentice H, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28(Suppl B):83-91.
9. Lackner H, Schwinger W, Urban C, et al. Liposomal amphotericin B (AmBisome) for treatment of disseminated fungal infections in two infants of very low-birth-weight. Pediatrics 1992;89:1259-61.
10. Vincent M, Webster MH, Pether JVS. Liposomal amphotericin B. Lancet 1992;339:374-5.
11. da Silva LP, Amaral JMV, Ferreira NC. Which is the most appropriate dosage of liposomal amphotericin B (AmBisome) for the treatment of fungal infections in infants of very low birth weight? Pediatrics 1993;91:1217-8.
12. Sievers R, Neubauer AP, Natzschka J. Liposomal amphotericin B for treatment of a disseminated Candida infection with encephalitis and osteoarthritis in a preterm neonate. Monatsschr Kinderheilkd 1994;142:266-8.
13. Jarløv JO, Born P, Bruun B. Candida albicans meningitis in a 27 weeks premature infant treated with liposomal amphotericin B (AmBisome). Scand J Infect Dis 1995;27:419-20.
14. Evdoridou J, Roilides E, Bibashi E, Kremenopoulos G. Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997;25:112-6.
15. Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 1984;105:616-22.